KZR
Kezar Life Sciences, Inc.
NASDAQ · Healthcare · Biotechnology · US
$7.29
+0.00%Year over year
Reported trailing growth
- Revenue
- —
- EBITDA
- +48.5%
- EBIT
- +50.3%
- EPS
- -9.8%
- Free cash flow
- —
- Operating cash flow
- —
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- —
- EBITDA
- +36.7%
- EBIT
- +42.3%
- Net income
- +33.1%
- EPS
- —
- Free cash flow
- +30.2%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Mar 1, 2026